By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
IFF's divestment of its largest revenue segment to CVC at a low multiple reflects distressed conditions, but the 10% retained stake and CVC's turnaround plan offer potential upside. However, the prolonged closure timeline exposes IFF to further deterioration and regulatory risks.
Risk: Prolonged closure timeline leading to further deterioration and regulatory risks
Opportunity: Potential upside from CVC's turnaround plan and retained stake
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
International Flavors & Fragrances has agreed to sell its food-ingredients business to buyout firm CVC Capital Partners in a deal that values the division at $4.3 billion including debt.
IFF said Friday that it will retain a 10% stake in the division, partly to ensure continued cooperation between the company and the food-ingredients business. The stake will also allow IFF shareholders to benefit from any increase in the division’s value under CVC’s ownership, the company said.
- A Famous Math Problem Stumped Humans for 80 Years. AI Just Cracked It.
- The Billionaire Coding Genius Making the Tough Decisions at OpenAI
- Robotaxis Are Spreading Across the U.S.—and So Is the Backlash
- You Won the Battle on Investment Fees. You’re Losing the War Against Taxes.
The Wall Street Journal earlier reported that IFF was close to a deal with CVC.
New York-based IFF makes a variety of products, ranging from scents for perfumes to ingredients used in food that can help digestion. It has a market value of close to $20 billion.
IFF’s food-ingredients business produces emulsifiers used to make food production more efficient, sweeteners and paste for gelato among other products.
The division is IFF’s biggest by revenue, generating sales of almost $3.28 billion last year. However, sales fell year-over-year in 2025 and the company recently wrote down the value of the unit. The division did, though, report a rise in first-quarter revenue.
IFF said it expects to close the deal with CVC by the middle of next year.
The sale of the food-ingredients business is IFF’s latest move to boost profitability. The company has sold several assets since making a couple of big acquisitions in recent years, including a merger with DuPont’s nutrition business in 2021.
Last year, IFF sold its business that makes dietary supplements for up to $2.85 billion, including debt, to French ingredients producer Roquette. In March, IFF sold its soy crush and lecithin business to crop trader and processor Bunge for an undisclosed amount.
The deal also comes at a time when rival Ingredion is seeking to bulk up. Ingredion is currently in talks to buy U.K. ingredients maker Tate & Lyle, having recently made a takeover proposal worth about $3.7 billion.
Luxembourg-based CVC oversees about €209 billion in assets, equivalent to more than $243 billion.
This week, the buyout firm sold its minority stake in Spain’s Naturgy Energy for close to $3.6 billion.
CVC is widely known for its investments in the chemicals sector. Holdings include Brazilian lubricants business Moove and Netherlands-based chemicals producer AnQore.
Four leading AI models discuss this article
"Divesting the top-line dominant food-ingredients unit risks capping IFF's growth trajectory even if it improves reported margins."
IFF is shedding its largest revenue segment ($3.28B in 2024 sales) to CVC at $4.3B including debt while keeping a 10% stake, continuing a post-2021 DuPont merger pattern of asset sales after the recent $2.85B supplements divestiture. The unit posted Q1 revenue growth yet suffered a prior write-down and 2024 sales decline, suggesting the deal price may reflect depressed multiples. Closure is slated only for mid-2026, exposing IFF to prolonged execution and regulatory risk in a consolidating ingredients space where Ingredion is simultaneously bidding for Tate & Lyle.
The write-down and revenue dip may already price in the unit's weakness, so selling now could free IFF to redeploy capital into higher-margin fragrance or health businesses before further erosion occurs.
"IFF is selling its largest revenue driver at a depressed multiple while still carrying debt from failed acquisitions, signaling management's loss of strategic conviction rather than disciplined portfolio optimization."
IFF is shedding its largest revenue division at what appears to be a distressed valuation—$4.3B for a unit generating $3.28B in annual sales implies ~1.3x sales, well below typical food-ingredients multiples of 1.8–2.2x. The 10% retain stake is a fig leaf; it doesn't change that IFF is exiting scale. However, the real story is IFF's strategic incoherence. Post-DuPont merger (2021), IFF over-leveraged into nutrition/food. Now it's liquidating that thesis piece by piece. The company is effectively admitting the acquisition strategy failed. Closing mid-2026 leaves 12+ months of uncertainty. For CVC, this is a typical play—buy distressed assets cheap, de-lever, and flip—but IFF shareholders are funding the mistake.
IFF may be executing a disciplined portfolio reset: shedding low-margin, capital-intensive food assets to focus on higher-margin fragrances and flavors, which command better multiples and less cyclical demand. The 10% stake gives upside optionality if CVC successfully improves the unit's profitability.
"IFF is sacrificing its core revenue engine to cover the financial hangover from its ill-fated DuPont nutrition integration."
This divestiture is a desperate deleveraging play for IFF. At $4.3 billion, the valuation implies a mid-single-digit EBITDA multiple, reflecting the market’s lack of confidence in the unit's recent performance and the broader struggle to integrate the 2021 DuPont nutrition merger. While selling the division helps repair the balance sheet, IFF is essentially liquidating its highest-revenue segment to fund past acquisition mistakes. I am skeptical that shedding these assets will lead to organic growth; instead, it leaves IFF as a smaller, potentially less diversified entity in a volatile scent and fragrance market. The 10% retained stake is a hollow gesture that won't offset the loss of scale.
If CVC successfully optimizes the unit's supply chain and reverses the recent sales decline, IFF’s 10% stake could yield a significant windfall that validates the board's patience over a longer horizon.
"The deal can unlock value for IFF only if CVC meaningfully improves the unit’s profitability; otherwise the headline valuation and leverage imply significant execution risk and uncertain upside."
Initial read: IFF monetizes its largest unit for about $4.3B including the division’s debt, while keeping a 10% stake. That creates optionality on upside if CVC unlocks value, but the price hints at a levered, private-equity-led turnaround rather than a clean strategic sale. The food-ingredients unit posted $3.28B in sales last year, but declined in 2025 and was written down, signaling structural headwinds (pricing, raw materials, product mix). CVC’s playbook is financial engineering and cost discipline; execution risk is high. Missing context: the actual debt level, financing structure, synergy plan, and how IFF’s supply/innovation collaboration will work post-close.
This could be a distressed carve-out masquerading as value-creation; 'including debt' implies leverage on a unit whose economics have deteriorated, and the 10% stake may cap upside if CVC falters.
"Extended closure timeline amplifies execution risks in a consolidating market that none have quantified against IFF's remaining portfolio."
The 12-month-plus gap to mid-2026 closure, flagged by Grok and Claude, leaves IFF exposed to further deterioration in the food unit's performance while competitors consolidate. This timeline risk compounds the deleveraging benefits Gemini highlights, as any sales decline could force renegotiation or lower effective proceeds. The retained stake offers little buffer if CVC prioritizes its own returns over collaboration.
"Distressed valuation ≠ distressed asset; CVC's leverage capacity and operational playbook may justify the discount without confirming IFF's merger failure."
Claude and Gemini both frame this as distressed, but neither quantifies what 'distressed' means here. A 1.3x sales multiple on a $3.28B revenue unit is low—agreed—but food ingredients typically trade 1.8–2.2x in *healthy* markets. The real question: is IFF selling at 30–40% discount because the unit is broken, or because private equity can lever it 5–6x and still generate returns? If the latter, IFF isn't liquidating failure; it's selling optionality to a buyer with different risk appetite. The 12-month closure window is real friction, but it cuts both ways: CVC has time to signal early wins, which could validate the 10% stake's value before close.
"The extended closure timeline invites intense antitrust scrutiny that could force deal-breaking concessions or price renegotiations."
Claude, you’re missing the regulatory friction. The '12-month closure' isn't just operational; it’s a massive antitrust target. With Ingredion and Tate & Lyle already in a consolidation dance, global regulators will scrutinize the entire food-ingredients supply chain. If the FTC or EU competition authorities demand divestitures from the CVC-held entity, the deal value collapses. This isn't just about 'distressed' versus 'levered'—it's about whether this deal even survives the regulatory gauntlet in its current form.
"Regulatory hurdles could erase deal value and the 10% stake upside, making the 12-month close a major execution risk."
Gemini treats the divestiture as a straightforward deleveraging move. I’d flag the regulatory wildcard as the bigger risk: antitrust scrutiny, potential required divestitures, or deal restructuring could evaporate the $4.3B price and the 10% stake’s upside. A 12+ month close amplifies execution risk and could leave IFF with a smaller, less diversified base if regulators demand concessions, undermining any near-term deleveraging thesis.
IFF's divestment of its largest revenue segment to CVC at a low multiple reflects distressed conditions, but the 10% retained stake and CVC's turnaround plan offer potential upside. However, the prolonged closure timeline exposes IFF to further deterioration and regulatory risks.
Potential upside from CVC's turnaround plan and retained stake
Prolonged closure timeline leading to further deterioration and regulatory risks